| Gastroesophageal Junction Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 107show all (up to 200) |
|---|
| → investigated in trials for | Oxaliplatinsmall molecule 85 trials (41 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 85 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Fluorouracilsmall molecule 77 trials (31 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 77 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Paclitaxelsmall molecule 56 trials (28 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 56 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Capecitabinesmall_molecule 55 trials (31 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 55 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Pembrolizumabmonoclonal antibody 52 trials (19 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 52 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Leucovorinsmall molecule 44 trials (19 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 44 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Docetaxelsmall molecule 36 trials (14 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 36 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Cisplatinsmall molecule 33 trials (10 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 33 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Trastuzumabmonoclonal_antibody 28 trials (16 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 28 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Ramucirumabmonoclonal antibody 26 trials (10 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 26 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Irinotecansmall molecule 25 trials (9 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 25 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Nivolumabmonoclonal antibody 25 trials (16 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 25 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Carboplatinsmall molecule 19 trials (8 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 19 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Durvalumabmonoclonal_antibody 10 trials (5 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 10 | Observed | clinicaltrials | graph → |
| → investigated in trials for | Tislelizumabmonoclonal antibody 10 trials (8 active) · roll-up of the cancer and its descendants | — | — | Gastroesophageal Junction Adenocarcinoma | 10 | Observed | clinicaltrials | graph → |